Cargando…
Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with e...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391624/ https://www.ncbi.nlm.nih.gov/pubmed/34441297 http://dx.doi.org/10.3390/diagnostics11081362 |
_version_ | 1783743318274867200 |
---|---|
author | Meehan, Richard Thomas Amigues, Isabelle Anne Knight, Vijaya |
author_facet | Meehan, Richard Thomas Amigues, Isabelle Anne Knight, Vijaya |
author_sort | Meehan, Richard Thomas |
collection | PubMed |
description | Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with expensive, ineffective, or toxic drugs. This review will focus primarily on rheumatoid arthritis (RA) therapeutics where the need is greatest due to poor patient outcomes if the optimum drug is delayed. We will review current FDA-approved biologic and small molecule drugs and why RA patients switch these medications. We will discuss the sampling of various tissues for potential CDx and review early results from studies investigating drug responsiveness utilizing advanced technologies including; multiplex testing of cytokines and proteins, autoantibody profiling, genomic analysis, proteomics, miRNA analysis, and metabolomics. By using these new technologies for CDx the goal is to improve RA patient outcomes and achieve similar successes like those seen in oncology using precision medicine guided therapeutics. |
format | Online Article Text |
id | pubmed-8391624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83916242021-08-28 Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics Meehan, Richard Thomas Amigues, Isabelle Anne Knight, Vijaya Diagnostics (Basel) Review Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with expensive, ineffective, or toxic drugs. This review will focus primarily on rheumatoid arthritis (RA) therapeutics where the need is greatest due to poor patient outcomes if the optimum drug is delayed. We will review current FDA-approved biologic and small molecule drugs and why RA patients switch these medications. We will discuss the sampling of various tissues for potential CDx and review early results from studies investigating drug responsiveness utilizing advanced technologies including; multiplex testing of cytokines and proteins, autoantibody profiling, genomic analysis, proteomics, miRNA analysis, and metabolomics. By using these new technologies for CDx the goal is to improve RA patient outcomes and achieve similar successes like those seen in oncology using precision medicine guided therapeutics. MDPI 2021-07-29 /pmc/articles/PMC8391624/ /pubmed/34441297 http://dx.doi.org/10.3390/diagnostics11081362 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Meehan, Richard Thomas Amigues, Isabelle Anne Knight, Vijaya Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics |
title | Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics |
title_full | Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics |
title_fullStr | Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics |
title_full_unstemmed | Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics |
title_short | Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics |
title_sort | precision medicine for rheumatoid arthritis: the right drug for the right patient—companion diagnostics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391624/ https://www.ncbi.nlm.nih.gov/pubmed/34441297 http://dx.doi.org/10.3390/diagnostics11081362 |
work_keys_str_mv | AT meehanrichardthomas precisionmedicineforrheumatoidarthritistherightdrugfortherightpatientcompaniondiagnostics AT amiguesisabelleanne precisionmedicineforrheumatoidarthritistherightdrugfortherightpatientcompaniondiagnostics AT knightvijaya precisionmedicineforrheumatoidarthritistherightdrugfortherightpatientcompaniondiagnostics |